spacer.png, 0 kB
MyriaScreen Diversity Collection PDF Print E-mail
Press Releases
TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections.


Sigma-Aldrich Introduces the MyriaScreen Diversity Collection for Drug Discovery
Newark, DE, September 23, 2005 –(PR.COM)– TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical diversity while maintaining drug-likeness.

The MyriaScreen Diversity Collection was assembled from a pool of over 300,000 screening compounds using a combination of filters, diversity predictors, and manual selection. The resulting 10,000 compounds are drug-like, chemically diverse, and amenable to follow-up chemistry and optimization. The collection is well suited for researchers that are looking for a small, cost-effective, ready-to-screen set of high-quality screening compounds.
“MyriaScreen will complement our customers’ existing screening collections and jump-start new collections by quickly adding interesting chemotypes,” said Michael Earley, Product Manager, Drug Discovery, Sigma-Aldrich. “Our collaboration with TimTec, Inc. resulted in a high-quality library that our customers will find useful.”

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and chemical manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 34 countries and has 6,000 employees providing excellent service worldwide. We are committed to the success of our Customers, Employees and Shareholders through leadership in Life Science, High Technology and Service.

To request information about MyriaScreen, please click here.

Forward Inquiries to:
Mrs. Kelley Euchner, 800-521-8956
Mr. Timothy Sommer, 314-286-7768

About TimTec

TimTec Corporation is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.

For further information please contact:


TimTec Inc
Harmony Business Park Building 301-A
Newark DE 19711 USA
Tel 302 292 8500
Fax 302 292 8520
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.timtec.net

http://www.pr.com/press-release/3156

http://www.bioscreening.net

< Prev   Next >
 

Drug Discovery News

  • Novel ‘Antisense’ Therapies Protect Primates from Lethal Ebola and Marburg Viruses
    ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings. See Also: Health [...]
  • Molecular Target for Screening: G-Protein-Coupled Receptors
    Newark, DE. August, 2010 – Press Release – TimTec, LLC. – Molecular Target for Screening:  G-Protein-Coupled Receptors, ActiTarg-G G-Protein-Coupled Receptors are the largest gene families in the human genome and, rightfully so, have become the leading molecular target in 2008. In 2009 SBS April meeting in Lille, France, followed-up with screening trends report stating that  [...]
  • Actelion obtains option to acquire privately-held Trophos
    Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be further explored in drug discovery collaboration ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE – 20 July 2010 – Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby [...]
  • Screen for molecules that inhibit formation of A-beta oligomers
    Alzheimer’s disease (AD) is a devastating neurological disorder characterized by the deposition of aggregated proteins in the brain in the form of extracellular beta-amyloid in senile plaques and intracellular tau in neurofibrillary tangles. A current approach towards treatment of Alzheimer’s disease is by using inhibitors of amyloid beta aggregation. Current screening protocols for inhibitors of [...]
  • Nine U.S. Health Research Centers to Receive $255 Million
    Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes [...]
  • BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
    Saffron Walden and Bristol, UK; 16 July 2010 – BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain).  BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol.  Total [...]
  • NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012
    NIH has extended its agreement with Galapagos’ service division, BioFocus, for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. Galapagos will thus be eligible to receive up to $8.6 million over the course of the two-year extension. The NIH MLSMR collects samples for high-throughput biological screening and distributes them to [...]
  • Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaboration
    Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research  to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience [...]
  • Volatile Organic Compounds (VOCs) on the Gulf Coastline
    Resource: EPA – United States Environmental Protection Agency Volatile Organic Compounds (VOCs) on the Gulf Coastline EPA is analyzing air samples for volatile organic compounds (VOCs) – including specifically, benzene, ethylbenzene, toluene, and xylene. EPA is sampling for these pollutants because they are present in oil and because, at elevated concentrations, they may cause health [...]
  • The NIH Molecular Libraries Program: Identifying Chemical Probes for New Medicines
    Alice McCarthy In 2003, several program leaders within the National Institutes of Health (NIH) recognized that the results from the recently completed Human Genome Project were a launching pad for further study. Now that scientists knew the genome, how could they determine gene function? In particular, how could scientists find specific biological pathways and targets that [...]

Latest News and Articles

info@timtec.net Harmony Business Park Building 301-A Newark, DE 19711
Toll free 800-574-7391 T: 302-292-8500  F: 302-292-8520
spacer.png, 0 kB